PrintFriendly

Print Friendly, PDF & Email

Current and Emerging Therapies the Focus of New Medscape Activity

January 5, 2018

Medscape recently launched a new education opportunity for healthcare providers. “Hemophilia 2018: Current and Emerging Therapies” is a discussion focused on the latest advances in the management of hemophilia, including the evolving role of extended half-life factor products, emerging data on small molecule approaches and gene therapy. The activity, which centers on a video recording of a live presentation at the 2017 American Society of Hematology Annual Meeting, is intended for hematologists, pediatricians, and other healthcare professionals who treat patients with hemophilia.

Upon completion, participants will:

  • Have increased knowledge regarding the
    • Advances in pressing issues in hemophilia, such as inhibitors, monitoring, and joint health
    • Outcomes from long-term efficacy and safety assessments of established extended half-life (EHL) factor products
    • Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies
  • Have greater confidence in their ability to
    • Use EHL factor products appropriately in patients with hemophilia

Hemophilia 2018: Current and Emerging Therapies
Steven W. Pipe, MD; Stacy E. Croteau, MD, MMS; Michael U. Callaghan, MD;
John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPCH
CME / ABIM MOC / CE Released: 12/20/2017 Valid for credit through: 12/20/2018

If you are already registered with Medscape follow this link to access this activity. If you are not registered, simply go to Medscape.org where registration is straightforward and free of charge.